Evidence for an exclusive association of matrix metalloproteinase-9 with dysfunctional high-density lipoprotein: A novel finding

Atherosclerosis

Volumn 236, Issue 1, 2014, Pages

  Sini, S ^a   Deepa, D ^a   Harikrishnan, S ^a   Jayakumari, N ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

Atherosclerosis; Dysfunctional HDL; Inflammation; Matrix metalloproteinase 9; Molecular docking

Indexed keywords

ACUTE PHASE PROTEIN; ANTIOXIDANT; GELATIN; GELATINASE B; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; IL10 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN; MACROGOL DERIVATIVE; MMP9 PROTEIN, HUMAN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DENSITY GRADIENT CENTRIFUGATION; ELUTION; ENZYME ACTIVITY; FEMALE; HUMAN; IN VITRO STUDY; INFLAMMATION; ISOLATION PROCEDURE; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MALE; MOLECULAR DOCKING; MONOCYTE; OXIDATION; PRECIPITATION; PRIORITY JOURNAL; WESTERN BLOTTING; ZYMOGRAPHY; BIOSYNTHESIS; BLOOD; CARDIOVASCULAR DISEASES; CELL CULTURE; ENZYMOLOGY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; RISK;

ADULT; BLOTTING, WESTERN; CARDIOVASCULAR DISEASES; CELLS, CULTURED; CENTRIFUGATION, DENSITY GRADIENT; CHEMICAL PRECIPITATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; INTERLEUKIN-10; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MONOCYTES; OXIDATION-REDUCTION; POLYETHYLENE GLYCOLS; PROTEIN INTERACTION MAPPING; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905837128     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.06.007     Document Type: Article

References (35)

1. Hegele R.A. The genetic basis of atherosclerosis,. Int J Clin Lab Res 1997, 27:2-13.
2. Goldbourt U., Yaari S., Medalie J.H. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997, 17:107-113.
3. Miller G.J., Miller N.E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975, 1:16-19.
4. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study,. Am J Med 1977, 62:707-714.
5. Prospective Studies C., Lewington S., Whitlock G., Clarke R., Sherliker P., Emberson J., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839.
6. Briel M., Ferreira-Gonzalez I., You J.J., Karanicolas P.J., Akl E.A., Wu P., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009, 338:b92.
7. Baron A.A., Baron S.B. High levels of HDL cholesterol do not predict protection from cardiovascular disease in women. Prev Cardiol 2007, 10:125-127.
8. G H.B., Rao V.S., Kakkar V.V. Friend turns foe: transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response. Cholesterol 2011, 2011:274629.
9. Ansell B.J., Fonarow G.C., Fogelman A.M. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007, 18:427-434.
10. Van Lenten B.J., Wagner A.C., Nayak D.P., Hama S., Navab M., Fogelman A.M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 2001, 103:2283-2288.
11. Sini S., NJ Functionally defective high density lipoprotein is pro-oxidant: a deviation from normal atheroprotective character. Int J Nutr Food Sci 2013, 2:92-101. doi: 110.11648/j.ijnfs.20130203.20130211.
12. Eren E., Yilmaz N., Aydin O. High density lipoprotein and its dysfunction. Open Biochem J 2012, 6:78-93.
13. Calabresi L., Gomaraschi M., Franceschini G. High-density lipoprotein quantity or quality for cardiovascular prevention?. Curr Pharm Des 2010, 16:1494-1503.
14. Kontush A., Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374.
15. Smith J.D. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2010, 30:151-155.
16. Asleh R., Blum S., Kalet-Litman S., Alshiek J., Miller-Lotan R., Asaf R., et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 2008, 57:2794-2800.
17. Lindstedt L., Saarinen J., Kalkkinen N., Welgus H., Kovanen P.T. Matrix metalloproteinases-3, -7, and -12, but not -9, reduce high density lipoprotein-induced cholesterol efflux from human macrophage foam cells by truncation of the carboxyl terminus of apolipoprotein A-I. Parallel losses of pre-beta particles and the high affinity component of efflux. JBiol Chem 1999, 274:22627-22634.
18. Wagner D.R., Delagardelle C., Ernens I., Rouy D., Vaillant M., Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. JCard Fail 2006, 12:66-72.
19. Dormán G., Kocsis-Szommer K., Spadoni C., Ferdinandy P. MMP inhibitors in cardiac diseases: an update. Recent Pat Cardiovasc Drug Discov 2007, 2:186-194.
20. Watanabe N., Ikeda U. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep 2004, 6:112-120.
21. Lumb P.J., Slavin B.M. Determination of serum cholesterol concentration in the presence of ascorbate. J Clin Pathol 1993, 46:283-284.
22. Dulley J.R., Grieve P.A. Asimple technique for eliminating interference by detergents in the Lowry method of protein determination. Anal Biochem 1975, 64:136-141.
23. Izzo C., Grillo F., Murador E. Improved method for determination of high-density-lipoprotein cholesterol I. Isolation of high-density lipoproteins by use of polyethylene glycol 6000. Clin Chemistry 1981, 27:371-374.
24. Navab M., Hama S.Y., Hough G.P., Subbanagounder G., Reddy S.T., Fogelman A.M. Acell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. JLipid Res 2001, 42:1308-1317.
25. Toth M., Sohail A., Fridman R. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Biol 2012, 878:121-135.
26. Burnette W.N. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 1981, 112:195-203.
27. Jovinge S., Ares M.P., Kallin B., Nilsson J. Human monocytes/macrophages release TNF-alpha in response to Ox-LDL. Arterioscler Thromb Vasc Biol 1996, 16:1573-1579.
28. Lamarche B., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Després J.P. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the quebec cardiovascular study. Arterioscler Thromb Vasc Biol 1997, 17:1098-1105.
29. Soedamah-Muthu S.S., Chang Y.F., Otvos J., Evans R.W., Orchard T.J. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in type 1 diabetes. A prospective report from the pittsburgh epidemiology of diabetes complications study. Diabetologia 2003, 46:674-682.
30. Karlsson H., Leanderson P., Tagesson C., Lindahl M. Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5:1431-1445.
31. Rezaee F., Casetta B., Levels J.H., Speijer D., Meijers J.C.M. Proteomic analysis of high-density lipoprotein. Proteomics 2006, 6:721-730.
32. Watanabe J., Chou K.J., Liao J.C., Miao Y., Meng H.H., Helen Ge, et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. J Biol Chem 2007, 282:23698-23707.
33. Watanabe J., Grijalva V., Hama S., Barbour K., Berger F.G., Navab M., et al. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem 2009, 284:18292-18301.
34. Takeshita S., Tokutomi T., Kawase H., Nakatani K., Tsujimoto H., Kawamura Y., et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease, Clinical and experimental. immunology 2001, 125:340-344.
35. Shah P.K., Galis Z.S. Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation 2001, 104:1878-1880.